Evidence map›Paper›PMID 32543944›Full record

ArticleAmerican journal of physiology. Endocrinology and metabolism2020

Oligomeric collagen as an encapsulation material for islet/β-cell replacement: effect of islet source, dose, implant site, and administration format.

Clarissa Hernandez Stephens, Rachel A Morrison, Madeline McLaughlin, Kara Orr, Sarah A Tersey, J Catharine Scott-Moncrieff, Raghavendra G Mirmira, Robert V Considine, Sherry Voytik-Harbin

Open access · greenAbstract readComparative Study
In one paragraph

Article in American journal of physiology. Endocrinology and metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Clarissa Hernandez StephensWeldon School of Biomedical Engineering, Purdue University, West Lafayette, Indiana.
Rachel A MorrisonWeldon School of Biomedical Engineering, Purdue University, West Lafayette, Indiana.
Madeline McLaughlinWeldon School of Biomedical Engineering, Purdue University, West Lafayette, Indiana.
Kara OrrCenter for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, Indiana.
Sarah A TerseyCenter for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, Indiana.
J Catharine Scott-MoncrieffDepartment of Veterinary Clinical Sciences, Purdue University, West Lafayette, Indiana.
Raghavendra G MirmiraCenter for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, Indiana.
Robert V ConsidineCenter for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, Indiana.
Sherry Voytik-HarbinWeldon School of Biomedical Engineering, Purdue University, West Lafayette, Indiana.
Purdue University West Lafayette · USIndiana University School of MedicineIndiana University – Purdue University Indianapolis · US

Funding

Translation CoreP30DK097512 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI Carmella Evans-Molina · 2015 to 2026
$17.4M
Transcriptional Mechanisms Governing Beta Cell DifferentiationR01DK060581 · NIDDK · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Raghavendra G Mirmira · 2002 to 2026
$8.5M
Validation of small molecule 12-lipoxygenase inhibitors in metabolic diseaseR01DK105588 · NIDDK · UNIVERSITY OF CHICAGO · PI KULKARNI, ROHIT N., MIRMIRA, RAGHAVENDRA G · 2015 to 2024
$5.5M
Role of Polyamines and Hypusine in Nutrient-Induced Beta-Cell Growth and ReplicationR01DK124906 · NIDDK · UNIVERSITY OF CHICAGO · PI Raghavendra G Mirmira · 2020 to 2026
$4.0M
Interdisciplinary Bioengineering Training in Diabetes ResearchT32DK101001 · NIDDK · PURDUE UNIVERSITY · PI EVANS-MOLINA, CARMELLA, VOYTIK-HARBIN, SHERRY L · 2013 to 2022
$1.6M
Long-term non-enzymatic glucose sensor for an artificial pancreasR44DK101000 · NIDDK · PROFUSA, INC. · PI WISNIEWSKI, NATALIE ANN · 2016 to 2017
$1.5M
Late stage development and preparation of a long-term non-enzymatic continuous glucose sensor for clinical trialsSB1DK101000 · NIDDK · PROFUSA, INC. · PI GAMSEY, SOYA, REBRIN, KERSTIN · 2018 to 2019
$962k
Long-Term Non-Enzymatic Glucose Sensors for an Artificial PancreasR43DK101000 · NIDDK · PROFUSA, INC. · PI WISNIEWSKI, NATALIE ANN · 2013 to 2014
$252k
IUSM Center for Diabetes and Metabolic Diseases Pilot and Feasibility Program NIH grant P30 DK097512NIDDK NIH HHS P30 DK097512NIDDK NIH HHS R01 DK060581NIDDK NIH HHS R01 DK105588NIDDK NIH HHS R01 DK124906NIDDK NIH HHS R43 DK101000NIDDK NIH HHS R44 DK101000NIDDK NIH HHS SB1 DK101000NIDDK NIH HHS T32 DK101001NIH HHS R01 DK060581NIH HHS R01 DK105588NIH T32 Indiana Bioengineering Interdisciplinary Training for Diabetes Research Program NIDDK T32DK101000
6 · The paper itself

Abstract

Replacement of islets/β-cells that provide long-lasting glucose-sensing and insulin-releasing functions has the potential to restore extended glycemic control in individuals with type 1 diabetes. Unfortunately, persistent challenges preclude such therapies from widespread clinical use, including cumbersome administration via portal vein infusion, significant loss of functional islet mass upon administration, limited functional longevity, and requirement for systemic immunosuppression. Previously, fibril-forming type I collagen (oligomer) was shown to support subcutaneous injection and in situ encapsulation of syngeneic islets within diabetic mice, with rapid (<24 h) reversal of hyperglycemia and maintenance of euglycemia for beyond 90 days. Here, we further evaluated this macroencapsulation strategy, defining effects of islet source (allogeneic and xenogeneic) and dose (500 and 800 islets), injection microenvironment (subcutaneous and intraperitoneal), and macrocapsule format (injectable and preformed implantable) on islet functional longevity and recipient immune response. We found that xenogeneic rat islets functioned similarly to or better than allogeneic mouse islets, with only modest improvements in longevity noted with dosage. Additionally, subcutaneous injection led to more consistent encapsulation outcomes along with improved islet health and longevity, compared with intraperitoneal administration, whereas no significant differences were observed between subcutaneous injectable and preformed implantable formats. Collectively, these results document the benefits of incorporating natural collagen for islet/β-cell replacement therapies.

Indexed as

CollagenAllograftsAnimalsBlood GlucoseCell EncapsulationCell SurvivalDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 1Graft SurvivalHeterograftsInjections, IntraperitonealInjections, SubcutaneousInsulin-Secreting CellsIslets of LangerhansIslets of Langerhans TransplantationMiceBlood GlucoseCollagenislet encapsulationislet/β-cell replacementtype 1 diabetestype I oligomeric collagen

Identifiers

PMID32543944
PMCPMC7473915
OpenAlexW3034326870

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.